Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population pharmacokinetics of high-dose tigecycline in CRE/CRAB lower respiratory tract infection
ChiCTR-OPC-17013025Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigecycline in pulmonary infection, Enterobacteriaceae infection and Acinetobacter baumannii infection (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Plasma concentration of tigecycline. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
tigecycline
03
Conditions
pulmonary infectionEnterobacteriaceae infectionAcinetobacter baumannii infection
Beyond the preview
Go deeper on ChiCTR-OPC-17013025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013025.